VEGFA and cancer: Additionally, we observed a decrease in the number of cancer-associated fibroblast (CAF) secretory cells and a reduction in the expression of vascular endothelial growth factors (VEGFs) in the Treat sample, suggesting that FOLFOX-Bev treatment may hinder the secretory function of CAFs and potentially impede angiogenesis (Figures S6I–K).